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To the Editor:
In critically ill COVID-19 patients, a hyper-inflammatory host response contributes to organ 
dysfunction and death. The role of complement in these events is unclear. Complement 
activation yields powerful pro-inflammatory effectors, notably C5a and membrane attack 
complex, and triggers coagulation (1); it has been implicated in bacterial sepsis and septic 
shock, sepsis-like syndromes associated with coronavirus infections, and COVID-19-
associated microvascular injury and thrombosis (2-4).  Recently, the C5a/C5aR1 axis was 
implicated in COVID-19 lung pathology (5). We here report the contribution of complement 
activation and impact of complement blockade in severe COVID-19, defined as marked 
respiratory impairment requiring intensive care and ventilation support. Drugs were 
administered under the Managed Access Program and permission to undertake this case 
series study was granted by the Director of Research and Development at Cardiff and Vale 
University Health Board. 
Complement dysregulation was identified in critically ill, RT-PCR-confirmed COVID-19 
patients; terminal complement complex (TCC) and C5a levels were measured in 
mechanically ventilated patients on the Critical Care Unit at a single centre if the clinician 
considered that the clinical trajectory was not improving (Figure 1A). Five patients were 
selected, based on high levels of TCC (above the mean +2sd for controls; 7.14mg/L) and 
either treatment failure (Patients 1-3) or failure to improve (Patients 4 and 5) where death 
was not considered imminent (clinical judgement), for inclusion in a compassionate use 
study of complement blockade using LFG316 (tesidolumab; Novartis Managed Access 
Programme), a C5-blocking monoclonal antibody (mAb) that prevents generation of the pro-
inflammatory effectors C5a and membrane attack complex (6). As patients were unable to 
Page 3 of 12
 AJRCCM Articles in Press. Published September 08, 2020 as 10.1164/rccm.202007-2778LE 
 Copyright © 2020 by the American Thoracic Society 
provide written informed consent, assent from relatives was obtained. Pre-treatment 
disease course is summarised in Table 1. All five patients selected were paralysed and 
proned whilst receiving mechanical ventilation.  HFOV and Nitric oxide (NO) were used 
alone or in combination in the first three patients. Duration of ventilation prior to LFG316 is 
shown in Table 1. Each patient received a single 1500mg dose of LFG316 by intravenous 
infusion, anticipated from unpublished Novartis data to fully inhibit C5 for >7 days, 
preceded by chlorpheniramine (4mg) and hydrocortisone (100mg). Antibiotic prophylaxis 
(phenoxymethylpenicillin or clarithromycin) was provided to mitigate risk of encapsulated 
bacterial infections. In all patients, CH50 was completely suppressed up to day 4 post-
treatment with partial recovery at day 7; TCC and C5a levels fell to within the normal range 
and remained low through day 7; CRP levels were elevated pre-dose and, except for patient 
5, fell post-drug (~80%) and remained reduced through day 7 (Table 1). Patients 1,2 and 4 
showed rapid resolution of CRP, improved oxygenation and CO2; recovery in patient 3 was 
much slower but all showed improved ventilation post-drug (Figure 1B).  Patient 5 failed to 
respond to LFG316 despite complete complement blockade, developed a sudden pulseless 
electrical activity cardiac arrest and died 9 days after treatment; uniquely, CRP levels did not 
fall post-treatment in this patient, suggesting that there was another driver of inflammation, 
likely the identified occult Klebsiella infection. Among our severe COVID-19 cohort who did 
not receive LFG316, 67 of 71 were mechanically ventilated and paralysed, and 28 of these 
were proned. Mean duration of ventilation in this subgroup was 19.5 days. Death occurred 
in 13 (46.4%). 
Currently there are no proven effective therapies for critically ill COVID-19 patients requiring 
mechanical ventilation (7). The potential efficacy of anti-complement drug therapy in COVID-
19 has been tested in a handful of patients to date and was recently reviewed (8). Diurno et 
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al treated four COVID-19 patients with the C5 blocking mAb eculizumab, weekly x4 (9). All 
were self-ventilating with moderately elevated CRP that fell after treatment; all recovered 
over 14 days. Mastaglio et al treated a single non-ventilated patient with the C3 blocker AMY-
101 continuously infused over 14 days with favourable outcome (10).  In each of these 
reports, patients selected had relatively mild disease and no measurements of complement 
parameters to assess dysregulation before or in response to drug were reported. 
We describe a preliminary evaluation of the potential benefit of C5 blockade in severe COVID-
19; we show that the C5 blocking mAb LFG316 could be administered in critically ill 
mechanically ventilated COVID-19 patients; a single dose of LFG316 blocked C5 activity and 
complement activation for at least 4 days in all treated patients. In four of five patients, there 
was sustained improvement in clinical state persisting beyond C5 blockade. An occult 
Klebsiella infection was found in the non-responding patient 5 four days post-drug; given the 
known impact of complement blockade on risk of infection with gram-negative bacteria, it is 
possible that LFG316 treatment exacerbated the infection. No other adverse effects of 
therapy were seen in any of the treated patients. Our results suggest that transient blockade 
of C5 is sufficient to interrupt the hyper-inflammatory cycle in severe COVID-19 and permit 
recovery even in the most extreme clinical situations. This finding differs from previous case 
reports of complement inhibition in COVID-19 where patients were less severely ill and 
treated for extended periods (8-10). Our data are supportive of ongoing clinical trials of C5 
blockade in severe COVID-19 and may inform design of current and future trials of anti-
complement drugs where repeated or prolonged complement blockade are proposed; 
indeed, prolonged complement blockade may not only be unnecessary for patient benefit but 
may be harmful by increasing infection risk, a known consequence of complement blockade, 
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over weeks or months in recovering patients, likely on other immune suppressants and with 
residual lung damage. 
Study limitations include small cohort size and lack of a randomised control group. Although 
our data identify complement dysregulation and support clinical benefit of complement 
blockade in severe COVID-19, these limitations make it impossible to demonstrate proof-of-
efficacy. Further studies are warranted to confirm impact of complement blockade on hyper-
inflammatory and/or thrombotic components of COVID-19 disease and to establish optimal 
timing and dosing.
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Figure 1. Complement activation in severe COVID-19 and response to C5 blockade. 
A. Levels of terminal complement complex (TCC; in house ELISA), C5a (Hycult ELISA) and 
C5 (in house ELISA) were measured in EDTA plasma from severe COVID-19 patients and 
controls; TCC levels were significantly elevated compared to the healthy EDTA plasma 
controls (COVID-19, n=25, mean=12.5mg/L; controls n=67, mean=4.1mg/L; p<0.0001, 
unpaired t-test). C5a levels were also significantly elevated compared to healthy controls 
(COVID-19, n=25, mean 43.0µg/L; controls, n=32, mean=14.7µg/L; p<0.0001, unpaired T 
test). C5 levels were not different between COVID-19 (n=25; mean=84.5g/L) and controls 
(n=31, mean=81.8g/L; p= 0.42). Error bars are standard error in each panel. Control samples 
were from a healthy adult donor EDTA plasma set that had previously been collected in the 
laboratory.
B. Serial trends in PaO2:FiO2 ratio and PaCO2 were measured following LFG316 treatment. 
Plots represent the means ± 1 standard deviation from arterial blood gas measures taken on 
the specified day from each of the five patients (labelled below) administered LFG316. Filled 
squares are Pa02:FiO2 ratios, open circles are PaCO2 levels. Dotted lines indicate grading of 
Acute Respiratory Distress syndrome (mild: 200-300mmHg; Moderate: 100-200mmHg; or 
Severe: <100mmHg); grey zone represents normal range for PaCO2. Rapid clinical 
improvement in patient 4 leading to extubation on day 3 post-drug obviated the requirement 
for additional measures.
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Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Demographics Male56 years
Female
40 years
Male
46 years
Female
51 years 
Male
74 years
Past medical history:
Oesophagitis, psoriasis, 
allergic rhinitis and 
hypogonadism
Type 2 diabetes, depression, 
post-traumatic stress disorder, 
morbid obesity
Lambert Eaton syndrome, 
glaucoma, type 2 diabetes, 
penile carcinoma in situ,
Asthma
Hypertension; awaiting 
surgery for a benign 
posterior fossa tumour (on 
dexamethasone)
Pre-hospital symptomatic period: 8 days 5 days. 10 days 7 days 9 days
Time from hospital admission to LFG316 admin 34 days 7 days 22 days 12 days 11 days
Inpatient course, pre-LFG316
4 days of mechanical 
ventilation on ICU early in 
COVID course before ward 
discharge for 14 days, then. 
ICU readmission.
Rapid escalation to critical care 
within 48 hours of hospital 
admission.
Rapid escalation to critical 
care within 12 hours of 
hospital admission.
Admitted to critical care day 
3 after hospital admission 
with severe respiratory 
failure. 
Admission to critical care 1 
day after hospital admission 
with severe hypoxia. 
Pre-drug Steroids† 3.75g 0.3g 0 0.45g 0.48g
Ventilation duration 
pre-LFG316 4 plus 12 days 5 days 22 days 9 days 11 days
High frequency 
oscillatory ventilation No Yes Yes No No
Nitric oxide Yes Yes No No No
ECMO referral No Yes No No No
Prone Yes Yes Yes Yes Yes
Paralysis Yes Yes Yes Yes Yes
ICU course:
Pulmonary emboli Yes No No No Yes
Normal range/units Pre-
drug
First 
480
Day 
7-10
Pre-
drug
First 
480
Day 
7-10
Pre-
drug
First 
480
Day 
7-10
Pre-
drug
First 
480
Day 
7-10
Pre-
drug
First 
480
Day 
5-8
Haemoglobin 130 - 180 g/L 90.0 92.0 90.0 90.0 102 96.0 90.0 78.0 73.0 93.0 91.0 113 114 116 98.0
Platelets 150 – 400 x109/L 305 342 371 99 480 428 99 75 35 241 227 358 339 324 393
Neutrophils 1.7-7.5 x109/L 7.5 8.2 10.4 17.4 26.2 10.5 17.4 9.9 4.6 5.2 6.3 3.5 7.5 7.3 8.0
Lymphocytes 1.0-4.5 x109/L 1.5 1.1 1.6 0.9 3.0 1.4 0.9 0.4 0.1 1.0 1.2 1.7 1.3 1.0 1.9
Prothrombin Time 9.0- 13.0 seconds 13.0 11.7 - 12.3 13.0 13.0 11.4 - 12.1 12.9 12.6 - 13.0 12.5 13.5
Activated partial 
thromboplastin time
23.0-38.0 seconds 37.8 39.2 - 28.6 30.9 34.2 33.5 - 29.2 29.3 32.0 - 30.9 33.0 34.5
Fibrinogen 2.0-4.0 g/L 6.3 6.0 - 8.5 6.0 7.2 5.4 - 4.0 11.3 7.7 - 8.8 7.7 10.0
C3 0.75 - 1.65 g/L 2.13 1.86 2.03 1.80 1.67 1.93 1.12 1.17 1.22 1.54 1.73 2.02 1.49 1.36 2.00
C4 0.14 - 0.54 g/L 0.45 0.43 0.45 0.30 0.28 0.40 0.27 0.30 0.32 0.24 0.30 0.36 0.10 0.15 0.21
C5 80.5 – 86.2 mg/L 76.9 75.2 93.4 71.3 80.4 94.7 86.5 76.1 78.9 103.5 94.8 92.9 - - -
C5a 8.8 – 22.3  µg/L 119.1 28.6 16.8 36.1 22.1 15.6 28.0 16.8 18.6 31.4 22.0 26.5 - - -
Terminal Complement 
Complex (TCC)  1.2-7.2 mg/L 17.3 6.5 3.3 13.1 3.2 8.6 10.3 3.8 5.3 11.3 5.5 12.9 12.4 2.1 7.6
Classical pathway 
haemolytic activity (CH50)
70-130 Haemolytic 
units (HU) 229.8 0 175.1 132.2 0 69.9 284.4 0 88.9 268.4 0 105.5 247.9 0 151.5
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C-reactive protein <5 mg/L 99 31 8 170 36 59 113 22 24 164 43 27 133 182 149
Ferritin 15-300 μg/L 666 599 354 350 266 169 3004 - 384 473 248 - 424 421 508
Lactate Dehydrogenase 125-200 U/L 478 329 469 500 533 370 571 - 287 306 241 - 313 315 326
Procalcitonin <0.05 μg/L 0.14 0.08 0.05 0.57 0.27 0.20 3.27 3.09 1.01 0.08 0.05 - 1.32 0.48 0.66
0-34 ng/L (male) 23 13 12 - - - 89 - 46 - - - 9 20 44Troponin I
(high sensitivity) 0-16 ng/L (female) - - - <2 <2 3 - - - 2 <2 - - - -
Follow-up duration††
Days since 
admission (post 
LFG316)
81 (48) 50 (43) 63 (42) 49 (38) 20 (8)
Current care level††† 1-6 1 1 3 1 6 
†-  Steroids, total prednisolone equivalent dose given on CCU prior to administration of LFG316; in a comparator group of 28 clinically matched patients, steroid dose was 0.95g (sd +/- 0.27g).
††-Correct at date of original submission, 12th June 2020; censored at day 20 post admission for patient 5.
†††-Care level at date of submission defined by six-point scale consisting of the following categories 1, not hospitalized; 2, hospitalized, not requiring supplemental oxygen; 3, hospitalized, requiring supplemental oxygen; 
4, hospitalized, requiring nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both; 5, hospitalized, requiring invasive mechanical ventilation, ECMO, or both; and 6, death. 
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